Form 4: CFO Stephen Feider Sells BBNX Shares Under 10b5-1 Plan

Beta Bionics CFO Stephen Feider exercised options and sold 100 shares of common stock on September 5, 2025, under a pre-arranged 10b5-1 plan.

Summary

• Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions on September 5, 2025.
• Feider exercised an employee stock option to acquire 100 shares of common stock at an exercise price of $5.10 per share.
• Concurrently, Feider sold 100 shares of common stock at a price of $21.00 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
• Following these transactions, Feider directly owns 44,041 shares of common stock.
• Feider also holds 99,595 employee stock options with an exercise price of $5.10, which vest in 48 equal monthly installments from September 14, 2023.

Sentiment

Score: 5

Explanation: Neutral. The transactions are routine insider activity under a 10b5-1 plan, indicating pre-planned diversification or liquidity rather than a strong positive or negative signal about the company's immediate prospects.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned transaction rather than an immediate reaction to new information.
• The exercise price of the options ($5.10) is significantly lower than the sale price ($21.00), indicating a profitable transaction for the insider.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be interpreted as a lack of conviction in the company's near-term stock price appreciation, although this is not always the case with planned sales.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency into insider trading activity, which can influence investor sentiment. The sale under a 10b5-1 plan suggests a pre-planned liquidity event rather than a reaction to new information.

Key Dates

Recommendation

The filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. This type of transaction typically does not provide new fundamental information about the company's operational performance or future prospects that would warrant a change in investment recommendation. It primarily reflects an individual's financial planning rather than a strong signal about the company's valuation.

Keywords

Beta Bionics, BBNX, Stephen Feider, CFO, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Equity Compensation